Pembrolizumab is approved for adjuvant treatment of renal cell carcinoma

Share This Post

Jan 2022: Pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with renal cell carcinoma (RCC) who are at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy plus resection of metastatic lesions.

Efficacy was assessed in 994 patients with intermediate-high or high risk of recurrence of RCC, or M1 no evidence of illness, in KEYNOTE-564 (NCT03142334), a multicenter, randomised (1:1), double-blind, placebo-controlled trial. Patients were given either pembrolizumab 200 mg intravenously every 3 weeks or placebo for up to a year, or until illness recurrence or intolerable toxicity, whichever came first.

Disease-free survival (DFS), defined as the period between recurrence, metastasis, or death, was the primary effectiveness outcome measure. Overall survival was another outcome metric (OS). A prespecified interim analysis revealed a statistically significant improvement in DFS, with 109 (22%) occurrences in the pembrolizumab arm and 151 (30%) events in the placebo arm (HR 0.68; 95 percent CI: 0.53, 0.87; p=0.0010). In neither arm, the median DFS was reached. OS data were not complete at the time of the DFS analysis, with 5% of the population dying.

Musculoskeletal discomfort, weariness, rash, diarrhoea, pruritus, and hypothyroidism were the most common adverse effects in this experiment (20 percent).

Pembrolizumab is given in doses of 200 mg every three weeks or 400 mg every six weeks until illness recurrence, intolerable toxicity, or up to 12 months.

 

Click here for full prescribing information for Keytruda.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy